December 3rd 2023
Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.
November 29th 2023
November 25th 2023
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
December 8, 2023
Register Now!
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Approves Olaparib for First-Line Maintenance in Gynecological Cancer
December 20th 2018The FDA has approved olaparib (Lynparza) as a maintenance treatment for patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy, as approved by an FDA-approved companion diagnostic assay.
FDA Grants Olaparib Priority Review for Frontline Maintenance in Ovarian Cancer
November 12th 2018The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for olaparib (Lynparza) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.
Olaparib Significantly Improves PFS in Advanced BRCA+ Ovarian Cancer
November 6th 2018The PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS) as frontline maintenance therapy in women with BRCA-positive advanced ovarian cancer, according to findings reported at the 2018 European Society of Medical Oncology Congress.
USPSTF Offers Choice in Testing for Women at Average Risk for Cervical Cancer
August 31st 2018New guidelines issued by the US Preventive Services Task Force (USPSTF) recommend for women aged 30 to 65 years at average risk for cervical cancer to choose to receive a Pap smear alone every 3 years, screening with the high-risk human papillomavirus test alone, or cotesting every 5 years.
Physicians With Personal Cancer Experience May Recommend Ovarian Cancer Screening Despite Guidelines
August 29th 2018A recent survey of physicians revealed that 17% of doctors with personal experience with cancer were more likely than those without to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
Tumor Treating Fields May Address Unmet Need in Ovarian Cancer Treatment
August 17th 2018The addition of tumor treating fields (TTF), an antimitotic therapy that delivers continuous low-intensity electrical fields to the tumor region, to weekly paclitaxel (Taxol) appeared safe in the treatment of patients with platinum-resistant ovarian cancer.
FDA Grants Breakthrough Therapy Designation to Drug Duo for Endometrial Cancer
August 2nd 2018The FDA has granted a second breakthrough therapy designation to the combination use of lenvatinib (Lenvima) and pembrolizumab (Keytruda) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy.
FDA Approves Bevacizumab Regimen for Ovarian Cancer Treatment After Surgery
June 13th 2018The FDA has approved bevacizumab (Avastin) for use in combination with carboplatin and paclitaxel, followed by bevacizumab monotherapy, for the treatment of patients with advanced ovarian cancer following initial surgical resection.
Simple, Evidence-Based Decision Aid Can Help Previvors and Their Nurses Weigh Prevention Options
May 20th 2018When a woman learns she carries a BRCA gene mutation—and thus, in her lifetime, faces an 87% risk of developing breast cancer and a 63% risk of getting ovarian cancer—she has a difficult decision-making process ahead of her. One nurse created an easy-to-understand guide that explains all options and their pros and cons, for use by oncology nurses working with BRCA mutation carriers who do not have cancer—previvors.
Changes in Olaparib Indications Demonstrate Need for Best Practices for Nurses
May 19th 2018As the Food and Drug Administration continues to approve additional indications for olaparib (Lynparza), health care providers and caregivers should be aware of the potential adverse effects (AEs) associated with treatment.